2-Aminophenoxazine-3-one suppresses the growth of mouse malignant melanoma B16 cells transplanted into C57BL/6Cr Slc mice

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 11, 2006, Pages 2197-2201

  Miyano Kurosaki, Naoko ^a   Kurosaki, Kunihiko ^b   Hayashi, Michiko ^b   Takaku, Hiroshi ^a   Hayafune, Masaaki ^a   Shirato, Ken ^c   Kasuga, Teruhiko ^d   Endo, Takahiko ^d   Tomoda, Akio ^d  

^a CHIBA INSTITUTE OF TECHNOLOGY   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c WASEDA UNIVERSITY   (Japan)

^d TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

In vivo anti tumor activity; Mouse malignant melanoma B16 cell; Phenoxazine

Indexed keywords

2 AMINOPHENOXAZINE 3 ONE; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; PHENOXAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; TUMOR VOLUME; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

ALANINE TRANSAMINASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ASPARTATE AMINOTRANSFERASES; BLOOD UREA NITROGEN; CELL LINE, TUMOR; CELL PROLIFERATION; CREATININE; FEMALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; OXAZINES; TIME FACTORS;

EID: 33750614422     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.2197     Document Type: Article

References (21)

1. Jemal A., Devesa S. S., Hartge P., Tucker M. A., J. Natl. Cancer Inst., 93, 678-683 (2001).
2. Pawlik T. M., Sondak V. K., Oncol. Hematol., 45, 245-264 (2003).
3. Chapman P. B., Einhorn L. H., Meyers M. L., Saxman S., Destro A. N., Panageas K. S., Begg C. B., Agarwala S. S., Schuchter L. L. M., Ernstoff M. S., Houghton An., Kirkwood J. M., J. Clin. Oncol., 9, 2745-2751 (1999).
4. Eton O., Legha S. S., Bedikian A. Y., Lee J. J., Buzaid A. C., Hodges C., Ring S. E., Papadopoulos N. E., Plager C., East M. J., Zhan F., Benjamin R. S., J. Clin. Oncol., 15, 2045-2052 (2002).
5. Runkle G. P., Znik A. J., Am. Fam. Physician, 49, 91-98 (1994).
6. Ishida R., Yamanaka S., Kawai H., Ito H., Iwai M., Nishizawa M., Hamatake M., Tomoda A., Anti-Cancer Drugs, 7, 591-595 (1996).
7. Abe A., Yamane M., Tomoda A., Anticancer Drugs, 12, 377-382 (2001).
8. Mori H., Honda K., Ishida R., Nohira T., Tomoda A., Anticancer Drugs, 11, 653-657 (2000).
9. Shimamoto T., Tomoda A., Ishida R., Ohyashiki K., Clin. Cancer Res., 7, 704-708 (2001).
10. Koshibu-Koizumi J., Akazawa M., Iwamoto T., Takasaki M., Mizuno F., Kobayashi R., Abe A., Tomoda A., Hamatake M., Ishida R., J. Cancer Res. Clin. Oncol., 128, 363-368 (2002).
11. Shimizu S., Suzuki M., Miyazawa K., Yokoyama T., Ohyashiki K., Miyazaki K., Abe A., Tomoda A., Oncol. Rep., 14, 41-46 (2005).
12. Hollstein U., Chem. Rev., 74, 625-652 (1974).
13. Shimizu S., Suzuki M., Tomoda A., Arai S., Taguchi H., Hanawa T., Kamiya S., Tohoku J. Exp. Med., 203, 47-52 (2004).
14. Masson F., Am. J. Pathol., 4, 181-211 (1928).
15. Hara K., Okamoto M., Aki T., Yagita H., Tanaka H., Mizukami Y., Nakamura H., Tomoda A., Hamasaki N., Kang D., Mol. Cancer Ther., 4, 1121-1127 (2005).
16. Eckert K. G., Eyer P., Biochem. Pharmacol., 32, 1019-1027 (1983).
17. Enoki E., Sada K., Qu X., Kyo S., Shahjahan Miah S. M., Hatani T., Tomoda A., Yamamura Y., J. Pharmacol. Sci., 94, 329-333 (2004).
18. Iwata A., Yamaguchi T., Sato K., Yoshitake N., Tomoda A., Biol. Pharm. Bull., 28, 905-907 (2005).
19. Fukuda G., Yoshitake N., Khan Z. A., Kanazawa M., Notoya Y., Che X. F., Akiyama S., Tomoda A., Biol. Pharm. Bull., 28, 797-801 (2005).
20. Musha S., Watanabe M., Ishida Y., Kato S., Konishi M., Tomoda A., Biol. Pharm. Bull., 28, 1521-1523 (2005).
21. Margolin K. A., Sondak V. K., "Cancer Management: A Multidisciplinary Approach," PRR, Inc., New York, 2002, pp. 471-510.